← Return to Waldenström's Macroglobulinemia

Discussion

Waldenström's Macroglobulinemia

Blood Cancers & Disorders | Last Active: May 25 10:40pm | Replies (135)
Comment receiving replies
@ejrquast

The following link will direct you to the 2022 Virtual Educational Forum - Multi-Omics for individuals by Dr. Treon: https://m.youtube.com/watch?v=yqns91T5Cmw


If you go to the Conclusion screen, you will see an easy to understand summary.
I happen o be an IWMF SG Leader and highly recommend the above mentioned resources. Also, the IWMF offers a Lifeline and you can contact patients for real life experiences, i.e. Zanubrutinib.
I took Ibrutinib, until it failed after just two years, but members respond well with fewer side effects with Zanubrutinib.
It is important to know your mutations prior to initiating any treatment.
Please feel free to contact me if you need assistance with IWMF resources.

Jump to this post

Replies to "The following link will direct you to the 2022 Virtual Educational Forum - Multi-Omics for individuals..."
jam5 | @jam5 | Apr 18, 2023

For a patient with MZL also with wtttr and AL cardiac amyloidosis in persistent Afib and taking Xarelto 20mg po OD, should there be a consideration for dose reduction of Xarelto 20 mg if recommended to take Brukinsa (Zanabrutinib 320 mg po OD)? Should the patient not take it?
Does the Brukinsa place the patient at increased risk of hemorrhage and stroke?
Previous Rituxan and Bendamustine infusions were discontinued after two cycles due to intolerability

VIEW AND REPLY